H3.3K27M peptide bound to HLA-A*02:01

The H3.3K27M peptide-HLA-A*02:01 complex is a molecular structure formed by the binding of a mutated decameric peptide from histone H3.3 (bearing a lysine-to-methionine substitution at position 27) to the HLA-A*02:01 MHC class I molecule. This complex can present the tumor-specific neoepitope to CD8+ T cells, thereby enabling immune recognition and therapeutic targeting of H3K27M-mutant gliomas. Multiple clinical efforts have developed peptide vaccines that stimulate this immune response in patients with HLA-A*02:01 and H3K27M-mutant diffuse midline glioma. While the target is considered immunologically actionable, challenges include low endogenous peptide presentation and the need for exogenous peptide loading or enhanced MHC presentation in target cells

Other names

H3.3K27M neoepitope-HLA-A*02:01 complexH3K27M peptide-HLA-A*02:01 complexH3.3K27M epitope-HLA-A*02:01

Presentation of H3.3K27M neoepitope enables cytotoxic T cell (CTL) recognition and targeting of tumor cells expressing the mutation; Vaccines stimulate a mutation-specific immune response, sometimes combined with checkpoint inhibition to enhance anti-tumor effects